

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5681390/publications.pdf>

Version: 2024-02-01

218
papers

33,866
citations

7561

77
h-index

3911

177
g-index

226
all docs

226
docs citations

226
times ranked

21020
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
3	Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2005, 128, 1898-1906.	0.6	1,703
4	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet, The</i> , 2001, 357, 1069-1075.	6.3	1,316
5	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
6	Liver fibrosis in overweight patients. <i>Gastroenterology</i> , 2000, 118, 1117-1123.	0.6	861
7	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
8	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
9	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
10	Viral hepatitis C. <i>Lancet, The</i> , 2003, 362, 2095-2100.	6.3	758
11	Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 730-739.	1.8	666
12	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
13	Endpoints and clinical trial design for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 54, 344-353.	3.6	617
14	Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. <i>Gastroenterology</i> , 2008, 135, 100-110.	0.6	575
15	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.	3.6	531
16	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528
17	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524
18	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	5.8	478

#	ARTICLE	IF	CITATIONS
19	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556.	1.8	421
20	Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. <i>Hepatology</i> , 2002, 35, 1485-1493.	3.6	414
21	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	1.8	401
22	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 6.	0.8	378
23	Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2008, 49, 831-844.	1.8	364
24	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 1941-1952.	3.6	355
25	NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016, 65, 1245-1257.	1.8	352
26	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
27	Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1209-1222.	1.9	328
28	Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 222-230.	1.8	322
29	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. <i>Hepatology</i> , 2010, 51, 445-453.	3.6	315
30	Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. <i>Comparative Hepatology</i> , 2004, 3, 8.	0.9	311
31	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013, 59, 859-871.	1.8	304
32	The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. <i>Comparative Hepatology</i> , 2005, 4, 10.	0.9	297
33	Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2004, 50, 1344-1355.	1.5	286
34	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	13.9	284
35	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	1.8	279
36	A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2011, 54, 1011-1019.	1.8	278

#	ARTICLE	IF	CITATIONS
37	Meta-analyses of FibroTest diagnostic value in chronic liver disease. <i>BMC Gastroenterology</i> , 2007, 7, 40.	0.8	268
38	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
39	Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 34.	0.8	245
40	Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. <i>World Journal of Gastroenterology</i> , 2011, 17, 3377.	1.4	244
41	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015, 62, S65-S75.	1.8	228
42	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. <i>Clinical Chemistry</i> , 2007, 53, 1615-1622.	1.5	227
43	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	3.6	227
44	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
45	A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2006, 52, 1887-1896.	1.5	210
46	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
47	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365.	0.8	178
48	Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). <i>BMC Gastroenterology</i> , 2010, 10, 40.	0.8	173
49	Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013, 58, 928-935.	1.8	151
50	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
51	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	3.7	142
52	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2012, 55, 419-428.	3.6	141
53	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683.	1.8	134
54	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125

#	ARTICLE	IF	CITATIONS
55	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
56	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. <i>PLoS ONE</i> , 2012, 7, e30325.	1.1	117
57	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
58	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014, 232, 99-109.	0.4	113
59	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 193-203.	1.9	112
60	The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2004, 39, 862-863.	3.6	111
61	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	0.8	105
62	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013, 19, 57.	1.4	104
63	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
64	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015, 61, 1041-1055.	3.6	102
65	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®] , [€]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 60, 706-714.	1.8	101
66	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	0.6	101
67	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , 2021, 27, 1825-1835.	15.2	98
68	Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 657-663.e7.	2.4	97
69	Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. <i>Hepatology</i> , 2008, 48, 2089-2089.	3.6	94
70	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016, 65, 95-102.	1.8	91
71	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 616-629.e26.	2.4	91
72	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000075.	1.1	90

#	ARTICLE	IF	CITATIONS
73	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports, 2019, 1, 188-198.	2.6	86
74	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 72, 627-635.	1.8	84
75	Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Alimentary Pharmacology and Therapeutics, 2007, 25, 733-739.	1.9	83
76	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials, 2020, 88, 105889.	0.8	80
77	Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard. Journal of Hepatology, 2012, 56, 541-548.	1.8	76
78	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver International, 2021, 41, 1227-1242.	1.9	76
79	Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers. PLoS ONE, 2008, 3, e3857.	1.1	75
80	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology, 2022, 76, 1030-1041.	1.8	74
81	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	0.8	71
82	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Alimentary Pharmacology and Therapeutics, 2016, 44, 877-889.	1.9	70
83	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology, 2022, 76, 536-548.	1.8	66
84	Breakthroughs in therapies for NASH and remaining challenges. Journal of Hepatology, 2022, 76, 1263-1278.	1.8	66
85	Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology, 2010, 52, 2206-2215.	3.6	65
86	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. Journal of Hepatology, 2012, 57, 541-548.	1.8	65
87	Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases. Clinical Gastroenterology and Hepatology, 2015, 13, 763-771.e6.	2.4	65
88	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology, 2019, 70, 1841-1855.	3.6	64
89	An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load. PLoS ONE, 2008, 3, e2573.	1.1	64
90	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. Gastroenterology, 2023, 165, 5-10.	0.6	59

#	ARTICLE	IF	CITATIONS
91	Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 828-831.	2.4	58
92	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011, 11, 39.	0.8	58
93	Pharmacological agents for NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 676-685.	8.2	58
94	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. <i>Journal of Hepatology</i> , 2018, 68, 353-361.	1.8	58
95	A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. <i>Journal of Hepatology</i> , 2012, 57, 376-383.	1.8	57
96	Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies. <i>Antiviral Therapy</i> , 2010, 15, 617-631.	0.6	56
97	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372.	6.1	56
98	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 279-289.	1.4	55
99	Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 23-28.	0.7	54
100	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	1.8	54
101	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	0.9	53
102	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142.	2.6	53
103	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	0.6	53
104	Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 207-218.	1.9	52
105	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	1.8	52
106	Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2011, 10, 87-97.	0.3	51
107	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
108	The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. <i>Journal of Hepatology</i> , 2006, 44, 1175-1185.	1.8	50

#	ARTICLE	IF	CITATIONS
109	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.	1.8	49
110	The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.	1.8	45
111	Randomized Study of Asunaprevir plus Pegylated Interferon- α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44
112	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 61, 994-1003.	1.8	42
113	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 30-36.	1.0	42
114	Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1724-1730.e5.	2.4	41
115	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. <i>Hepatology</i> , 2019, 69, 1453-1463.	3.6	41
116	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	2.4	41
117	Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy?. <i>Gastroenterology</i> , 2005, 128, 1146-1148.	0.6	40
118	Liver Stiffness by Transient Elastography to Detect Portal-Sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378.	3.6	40
119	Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 8-21.	0.9	39
120	Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. <i>Scientific Reports</i> , 2020, 10, 3850.	1.6	39
121	Non-alcoholic fatty liver "Perhaps not so benign". <i>Journal of Hepatology</i> , 2015, 62, 1002-1004.	1.8	38
122	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1398-1405.	1.1	35
123	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 165-178.	1.0	34
124	Non-pharmacological interventions in non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2017, 37, 90-96.	1.9	34
125	ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 388-396.	0.9	33
126	What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 290-295.	1.3	32

#	ARTICLE	IF	CITATIONS
127	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020, 2, 514-531.	5.1	31
128	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	2.6	31
129	NASH: a hidden and silent fibroser finally revealed?. <i>Journal of Hepatology</i> , 2005, 42, 12-14.	1.8	30
130	The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 262-269.	0.8	30
131	Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. <i>Hepatology</i> , 2022, 76, 1360-1375.	3.6	30
132	Treatment of NASH with ursodeoxycholic acid: Pro. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, S41-S45.	0.7	28
133	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127.	1.9	28
134	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019, 103, 28-38.	0.5	28
135	Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1081-1093.	1.9	27
136	European "NAFLD Preparedness Index" – Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234.	2.6	27
137	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300.	1.8	27
138	FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 720-730.	0.7	26
139	Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 992-999.e2.	2.4	26
140	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	3.7	26
141	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016, 11, e0163276.	1.1	26
142	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227.	1.8	25
143	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	0.8	25
144	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021, 74, 977-979.	1.8	25

#	ARTICLE	IF	CITATIONS
145	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2022, 76, 265-274.	1.8	24
146	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <i>Cell Reports Medicine</i> , 2020, 1, 100154.	3.3	23
147	Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials. <i>Journal of Hepatology</i> , 2017, 66, S54.	1.8	22
148	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. <i>Hepatology</i> , 2022, 76, 456-468.	3.6	22
149	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7.	2.4	21
150	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
151	Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Nutrition</i> , 2021, 8, 774030.	1.6	20
152	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 428-432.	0.6	19
153	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 59-66.	0.5	17
154	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	5.8	17
155	Touching some firm ground in the epidemiology of NASH. <i>Journal of Hepatology</i> , 2012, 56, 23-25.	1.8	16
156	Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 455-463.	0.7	16
157	Hepatic molecular effects of rosiglitazone in human nonalcoholic steatohepatitis suggest long-term proinflammatory damage. <i>Hepatology Research</i> , 2014, 44, 1241-1247.	1.8	16
158	Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, S294-S295.	1.8	16
159	Back to Byzance: Querelles byzantines over NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 1134-1136.	1.8	16
160	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 569-577.	0.8	15
161	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320.	1.9	15
162	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1.	0.6	15

#	ARTICLE	IF	CITATIONS
163	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
164	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015, 10, e0134302.	1.1	14
165	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436.	1.1	13
166	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 384-391.	0.8	13
167	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647.	1.4	13
168	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402.	0.8	12
169	A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. <i>Human Pathology</i> , 2010, 41, 1178-1185.	1.1	11
170	NAFLD: The evolving landscape. <i>Journal of Hepatology</i> , 2018, 68, 227-229.	1.8	11
171	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
172	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. <i>Digestive Diseases</i> , 2014, 32, 586-596.	0.8	10
173	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI est fini". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 432-439.	0.7	10
174	Genecriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study. <i>Journal of Hepatology</i> , 2018, 68, S1-S2.	1.8	10
175	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306.	1.1	10
176	Apolipoprotein A1 and hepatic fibrosis. <i>Journal of Hepatology</i> , 1995, 22, 107-10.	1.8	10
177	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013, 58, S46.	1.8	9
178	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015, 5, e010017.	0.8	9
179	Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S2-S3.	1.8	9
180	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9

#	ARTICLE	IF	CITATIONS
181	When the journey from obesity to cirrhosis takes an early start. <i>Journal of Hepatology</i> , 2016, 65, 249-251.	1.8	8
182	The painful reality of end-stage liver disease in NASH. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 8-10.	3.7	8
183	The EPoS staging system is a reproducible 7-tier fibrosis score for NAFLD adapted both to glass slides and digitized images (e-slides). <i>Journal of Hepatology</i> , 2018, 68, S553.	1.8	8
184	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 998-1007.	0.8	8
185	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7
186	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	1.4	7
187	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€”The POPâ€”NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777.	3.6	7
188	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	2.6	6
189	P832 CLINICAL VALIDATION OF THE FLIP ALGORITHM AND SAF SCORE IN NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S348.	1.8	4
190	Targeting non-alcoholic fatty liver disease through 11-Î²HSD1 inhibition. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 354-356.	5.5	4
191	Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S594-S595.	1.8	4
192	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2020, 37, 4627-4640.	1.3	4
193	Arterial hypertension as an uninvited player in hepatic stiffness?. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G942-G944.	1.6	3
194	Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S110-S111.	1.8	3
195	External validation of an algorithm combining multi-analyte blood tests (FibroTestâ€”LCR1â€”LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. <i>GastroHep</i> , 2019, 1, 146-153.	0.3	3
196	coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. <i>Hepatology Communications</i> , 2021, 5, 774-785.	2.0	3
197	The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test. <i>American Journal of Gastroenterology</i> , 2011, 106, 1853.	0.2	2
198	5 THE EMERGING IMPACT OF HEPATOCELLULAR CARCINOMA ARISING ON A BACKGROUND OF NAFLD. <i>Journal of Hepatology</i> , 2012, 56, S3.	1.8	2

#	ARTICLE	IF	CITATIONS
199	Pharmacological agents for nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013, 7, 833-841.	1.9	2
200	Letter: FibroTest for staging fibrosis in nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 655-656.	1.9	2
201	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2013, 159, 370.	2.0	2
202	Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". <i>Journal of Hepatology</i> , 2016, 65, 1267-1268.	1.8	2
203	Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2017, 66, S159-S160.	1.8	2
204	Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). <i>American Journal of Gastroenterology</i> , 2018, 113, 443-445.	0.2	2
205	Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. <i>Clinical Liver Disease</i> , 2021, 17, 398-400.	1.0	2
206	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
207	507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data. <i>Gastroenterology</i> , 2016, 150, S1037-S1038.	0.6	1
208	Screening studies of transient elastography and FibroTest in the general population. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246.	3.7	1
209	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
210	Clinicians' Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2707.	1.0	1
211	The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis. <i>Journal of Molecular Medicine</i> , 2022, 100, 1039-1042.	1.7	1
212	PWE-120 High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (>= 65 years) with nafld. <i>Gut</i> , 2015, 64, A265.1-A265.	6.1	0
213	Clinical endpoints are necessary in the interim analysis of REGENERATE " Authors' reply. <i>Lancet</i> , The, 2020, 396, 663-664.	6.3	0
214	Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. <i>Hepatology</i> , 2020, 71, 1146-1149.	3.6	0
215	Ökonomische Kosten und Gesundheitsfolgen von nicht-alkoholischer Fettleberhepatitis in den EU5 Ländern. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
216	Hepatic and Extrahepatic Malignancies in NAFLD. , 2016, , 271-290.		0

#	ARTICLE	IF	CITATIONS
217	The journey of a patient with biopsy-proven non-alcoholic steatohepatitis (NASH) – results from a real-world study. , 2019, 57, .		0
218	Pharmacological Options for NASH. , 2020, , 309-327.		0